Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Exome sequencing study on diffuse cutaneous systemic sclerosis

PROVIDER: PRJNA316441 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3305050_1.fastq.gz	Fastqsanger.gz
	SRR3305050_2.fastq.gz	Fastqsanger.gz
	SRR3305060_1.fastq.gz	Fastqsanger.gz
	SRR3305060_2.fastq.gz	Fastqsanger.gz
	SRR3305070_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

Project description:Systemic sclerosis (SSc) is an autoimmune disease characterized by inflammation and fibrosis of the skin and internal organs. We sought to assess the clinical and molecular effects associated with response to intravenous abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).

2016-02-01 | GSE66321 | GEO

Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial

2015-08-27 | GSE65405 | GEO

Homo sapiens

Project description:Stable gene expression of serial skin biopsies defines patient subsets in diffuse cutaneous systemic sclerosis

| PRJNA146381 | ENA

Myeloablation followed by autologous stem cell transplantation normalizes systemic sclerosis molecular signatures

Project description:This is global gene expression study of whole blood samples collected in the Cyclophosphamide Or Transplantation (SCOT) randomized controlled trial, as well as unaffected controls. Patients with diffuse cutaneous systemic sclerosis (scleroderma) received either myeloablation followed by autologous stem cell transplantation or intravenous cyclophosphamide

2019-07-10 | GSE130953 | GEO

Homo sapiens

Project description:Gene expression in limited cutaneous systemic sclerosis skin

| PRJNA308611 | ENA

Expression data from skin biopsies in pateints with systemic sclerosis treated with anti-TGF-beta, fresolimumab

Project description:Systemic sclerosis is associated with skin fibrosis thought mediated by TGFb. This open label clinical trial examines the effect of TGFb inhibition on skin gene expression. Patients 1-9 received two doses 1 mg/kg dose of fresolimumab at baseline and 3 weeks; patients 10-19 received a single 5 mg/kg dose Patients with diffuse cutaneous systemic sclerosis within 2 years of first raynauds had skin biopsies before treatment and the 3-4 weeks, 7 weeks and 24 weeks after treatment with fresolimumab

2015-06-05 | E-GEOD-55036 | biostudies-arrayexpress

RNA-seq of blood from donors with connective tissue diseases in the Lupus Extended Phenotype Cohort

Project description:The connective tissue diseases (CTDs) are group of inflammatory disorders with overlapping clinical and serological manifestations. We have undertaken Lupus Extended Phenotype (LEAP) study in of a cohort of adult patients with CTDs, namely systemic lupus erythematosus, Sjogren's syndrome, mixed and undifferentiated CTD, limited and diffuse cutaneous systemic sclerosis and dermatomyositis. RNAseq was undertaken in 12 participants from 4 ‘cohorts’ based on interferon stimulated gene and autoantibodies analyses: 3 ISG positive and anti-Smith positive participants; 3 ISG positive and anti-Smith negative participants; 3 ISG negative and anti-Smith positive participants and 3 ISG negative and anti-Smith negative participants.

2019-06-05 | E-MTAB-7080 | biostudies-arrayexpress

Homo sapiens

Project description:Gene expression from human keratinocytes isolated from limited systemic sclerosis (lcSSc) and diffuse systemic sclerosis (dcSSc) skin biopsy

| PRJNA320417 | ENA

Homo sapiens

Project description:Genome-Wide Association Study in Systemic Sclerosis

| PRJNA75871 | ENA

Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial

Project description:To assess the safety, efficacy, and molecular change associated with treatment of patients with early, diffuse cutaneous systemic sclerosis (dcSSc) with nilotinib (Tasigna™). In this open-label pilot trial 6 adult patients with early dcSSc received nilotinib. Primary endpoints were safety and change in modified Rodnan Skin Score (MRSS) after 6 months. Lesional skin biopsies at baseline, 6 and 12 months of treatment were assessed by histopathology, immunohistochemistry, and DNA microarray.

2015-08-27 | E-GEOD-65405 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data